Swayze Eric 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Eric Swayze Sells 15,642 Shares
What Happened
Eric Swayze, EVP Research at Ionis Pharmaceuticals (IONS), sold a total of 15,642 shares in open‑market transactions on February 13, 2026, for combined proceeds of about $1,278,914. The sales were: 9,435 shares at a weighted average price of $81.56 (proceeds $769,511) and 6,207 shares at a weighted average price of $82.07 (proceeds $509,403). Both transactions are reported as sales (S).
Key Details
- Transaction date: 2026-02-13 (both trades). Transaction type: open‑market sale (S).
- Prices: 9,435 shares at $81.56 (weighted average; actual trades ranged $80.76–$81.76, per footnote). 6,207 shares at $82.07 (weighted average; actual trades ranged $81.765–$82.315, per footnote).
- Total proceeds: ~$1,278,914.
- Plan/authorization: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted Aug 14, 2024 (footnote F1).
- Disclosure detail: Footnotes F2 and F3 note the reported prices are weighted averages and the filer can provide a breakdown of individual trade prices on request.
- Shares owned after transaction: Not specified in the excerpt provided — see the full Form 4 for post‑transaction holdings.
- Timeliness: Filing period and file date are both 2026-02-13, indicating the Form 4 was filed timely.
Context
These sales were executed under a pre‑arranged 10b5‑1 plan, which typically schedules trades in advance and is generally considered more routine than directional trading based on current company views. Sales are common for liquidity or diversification and do not, by themselves, indicate management’s view of the company’s prospects.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-13$81.56/sh−9,435$769,511→ 38,312 total - Sale
Common Stock
[F1][F3]2026-02-13$82.07/sh−6,207$509,403→ 32,105 total
- 318(indirect: by Son)
Common Stock
Footnotes (3)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.76 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.315 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.